We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Centene's Operational Execution Keep Margin Recovery on Track?
Read MoreHide Full Article
Key Takeaways
Centene is driving margin recovery through medical cost controls, AI tools and payment integrity efforts.
CNC improved Medicaid health benefits ratio to 93.1% and raised 2026 adjusted EPS guidance above $3.40.
Constructive Medicaid rate discussions could further support margin recovery and more consistent earnings.
Centene Corporation’s (CNC - Free Report) margin recovery story appears to be shifting from strategy to execution. The company has rolled out several initiatives to better manage medical costs, modernize and standardize processes, and strengthen payment integrity. With those efforts already contributing to stronger-than-expected first-quarter results, the focus now is on whether the momentum can sustain margin expansion.
Rather than relying solely on higher reimbursement rates, the insurer is tackling rising healthcare costs by standardizing utilization management, expanding clinical programs and optimizing provider networks through data analytics. It is also stepping up efforts to curb fraud, waste and abuse, while AI-enabled tools improve forecasting, detect abnormal claims earlier and strengthen cost discipline. Together, these measures should support more disciplined medical cost management and steadier profitability.
The operational gains are becoming visible. Medicaid's health benefits ratio improved 50 basis points year over year to 93.1%, marking the third consecutive quarter of progress. Stabilizing behavioral health trends and better oversight of applied behavior analysis (ABA) services further suggest the improvement is becoming increasingly structural. Reflecting the strong start, Centene raised its 2026 adjusted EPS guidance to more than $3.40.
Medical cost trends and reimbursement updates will remain key to sustaining Centene's margin recovery. Meanwhile, constructive Medicaid rate discussions should further enhance profitability by better aligning reimbursement with healthcare costs. Coupled with disciplined operational execution, these efforts position the insurer to continue improving margins and deliver more consistent earnings over time.
How Are Competitors Faring?
Some of CNC's major competitors in the managed care space are Elevance Health, Inc. (ELV - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) .
Elevance Health is focused on improving margins through operational discipline rather than relying solely on pricing. ELV continues to strengthen care management, expand value-based care arrangements and use advanced analytics to better manage medical costs across its Medicaid and Medicare businesses.
Molina Healthcare continues to focus on disciplined medical cost management and payment integrity to protect margins. Investments in care coordination, utilization management and technology have helped MOH manage healthcare costs while supporting consistent margin growth.
Shares of CNC have rallied 63.1% in the year-to-date period compared with the industry’s growth of 28.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Centene trades at a forward price-to-earnings ratio of 16.97, below the industry average of 18.55. CNC carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.46 per share, implying 66.4% growth from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Can Centene's Operational Execution Keep Margin Recovery on Track?
Key Takeaways
Centene Corporation’s (CNC - Free Report) margin recovery story appears to be shifting from strategy to execution. The company has rolled out several initiatives to better manage medical costs, modernize and standardize processes, and strengthen payment integrity. With those efforts already contributing to stronger-than-expected first-quarter results, the focus now is on whether the momentum can sustain margin expansion.
Rather than relying solely on higher reimbursement rates, the insurer is tackling rising healthcare costs by standardizing utilization management, expanding clinical programs and optimizing provider networks through data analytics. It is also stepping up efforts to curb fraud, waste and abuse, while AI-enabled tools improve forecasting, detect abnormal claims earlier and strengthen cost discipline. Together, these measures should support more disciplined medical cost management and steadier profitability.
The operational gains are becoming visible. Medicaid's health benefits ratio improved 50 basis points year over year to 93.1%, marking the third consecutive quarter of progress. Stabilizing behavioral health trends and better oversight of applied behavior analysis (ABA) services further suggest the improvement is becoming increasingly structural. Reflecting the strong start, Centene raised its 2026 adjusted EPS guidance to more than $3.40.
Medical cost trends and reimbursement updates will remain key to sustaining Centene's margin recovery. Meanwhile, constructive Medicaid rate discussions should further enhance profitability by better aligning reimbursement with healthcare costs. Coupled with disciplined operational execution, these efforts position the insurer to continue improving margins and deliver more consistent earnings over time.
How Are Competitors Faring?
Some of CNC's major competitors in the managed care space are Elevance Health, Inc. (ELV - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) .
Elevance Health is focused on improving margins through operational discipline rather than relying solely on pricing. ELV continues to strengthen care management, expand value-based care arrangements and use advanced analytics to better manage medical costs across its Medicaid and Medicare businesses.
Molina Healthcare continues to focus on disciplined medical cost management and payment integrity to protect margins. Investments in care coordination, utilization management and technology have helped MOH manage healthcare costs while supporting consistent margin growth.
Centene’s Price Performance, Valuation & Estimates
Shares of CNC have rallied 63.1% in the year-to-date period compared with the industry’s growth of 28.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Centene trades at a forward price-to-earnings ratio of 16.97, below the industry average of 18.55. CNC carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.46 per share, implying 66.4% growth from the year-ago period’s level.
Image Source: Zacks Investment Research
CNC stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.